Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial.
Henri J HuttunenSigrid BoomsMagnus SjögrenVera KerstensJarkko JohanssonRebecka HolmnäsJani KoskinenNatalia KulesskayaPatrik FazioMax WoolleyAlan BradyJulia WilliamsDavid JohnsonNarges DailamiWilliam GrayReeta LevoMart SaarmaChrister HalldinJohan MarjamaaJulio Resendiz-NievesIrena GruborGöran LindJohanna Eerola-RautioTuomas MertsalmiMattias AndréassonGesine PaulJuha O RinneRiku KivisaariHjalmar BjartmarzPer AlmqvistAndrea VarroneFilip ScheperjansHåkan WidnerPer SvenningssonPublished in: Movement disorders : official journal of the Movement Disorder Society (2023)
Intraputamenally administered CDNF was safe and well tolerated, and possible signs of biological response to the drug were observed in individual patients. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.